SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a potential breakout, fueled by discussions of flagging patterns and historical volume highs.  Enthusiasts are pointing to Litecoin's privacy features and the listing of companies holding LTC, while also drawing comparisons to Zcash's recent price movement. Bullish sentiment is further supported by the recent launch of Litecoin ETFs.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention, particularly for its strong community and unique branding. Discussions highlight its presence on multiple chains like Solana and Ethereum, facilitated by LayerZero, and its deflationary tokenomics. Community members are also excited about potential staking opportunities and partnerships.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid ongoing discussions around the Affordable Care Act (ACA) and its potential extension or repeal, with community members debating the implications for the company's revenue and future profitability. Some traders are also focusing on technical analysis, noting a long-term consolidation pattern, while others point to potential catalysts like earnings and ACA deal resolutions. The stock's high volatility and sensitivity to broader market trends are also being actively discussed.

Yearn Finance is a suite of products in Decentralized Finance (DeFi) that provides lending aggregation, yield generation, and insurance on the Ethereum blockchain. The protocol is maintained by various independent developers and is governed by YFI holders.  It started out as a passion project by Andre Cronje to automate the process of switching capital between lending platforms in search of the best yield offered, as the lending yield is a floating rate rather than fixed rate. Funds are shifted between dYdX, AAVE, and Compound automatically as interest rates change between these protocols.   The service offered includes major USD tokens such as DAI, USDT, USDC, and TUSD. For example, if a user deposits DAI into yearn.finance, the user will receive yDAI token in return, which is a yield-bearing DAI token.   Later on, it collaborated with Curve Finance to release a yield-bearing USD tokens pool that includes four y-tokens: yDAI, yUSDT, yUSDC and yTUSD, it is named as yUSD.   Yearn Finance debuted the vault feature after its token launch, igniting a frenzy on automated yield farming and is considered the initiator of the category of yield farming aggregator. Basically, the vault will help users to claim yield farming rewards and sell it for the underlying assets.   Vaults benefit users by socializing gas costs, automating the yield generation and rebalancing process, and automatically shifting capital as opportunities arise. End users also do not need to have proficient knowledge of the underlying protocols involved or DeFi, thus the Vaults represent a passive-investing strategy. It is akin to a crypto hedge fund where the aim is to increase the amount of assets that users deposited.

yearn.finance

Yearn.finance ($YFI) is surging amid community excitement, with many highlighting its small max supply of 36,000 tokens and potential for significant growth in the DeFi space as interest rates potentially decrease. Some community members are drawing comparisons to its previous peak and suggesting it could reach new all-time highs during this bull run, viewing it as a scarce asset poised for substantial gains. The conversation also includes discussions about its relationship to Bitcoin and Ethereum, with some anticipating a rotation of funds into YFI.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending as investors discuss its potential following a recent sell-off and upcoming earnings, with some seeing it as undervalued relative to peers like Palantir. Community members are highlighting contract wins, institutional ownership, and speculation around future deals, particularly in the nuclear and defense sectors, as potential catalysts. Some traders are attributing the recent price action to market manipulation and large shareholders.

Verge coin started its cryptocurrency journey in 2014, going by the name of DogecoinDark. The reason it was created was to create a truly private cryptocurrency. The founder of Verge felt that Bitcoin wasn’t anonymous, so he decided to build a new blockchain where transactions could not be traced. Verge uses multiple anonymity-centric networks such as TOR and I2P. The IP addresses of the users are fully obfuscated. The Core QT wallet has built-in TOR integration as well as SSL encryption which adds an extra level of security.  Verge is an open source project with an active team of developers from all over the world. The development team is always in close contact with the community. Verge is not a private company funded through an ICO or premining. Wraith Protocol is a technology upgrade package that enables our users to be able to send and receive payments privately across our blockchain by enabling stealth addressing services.   Additionally this update removes our QT wallet users off of clearnet and migrates everyone to SSL enabled Tor.  Verge focuses on security and maintaining user anonymity just like Monero; so that is its latent upside. Many investors are also applauding its unique technology. Having been improved and integrated with the Wraith Protocol technology, verge users are now able to effortlessly switch between private and public ledgers on the Verge blockchain.  Before this, private and public ledgers were mutually selected, meaning that they could not co-exist on a very similar blockchain. But investors are today free to use whatever ledger they want. A good example was when Wraith Protocol switched ON – one will not be able to view the transaction data, not even via the blockchain explorer. Additionally, Verge makes obscure the IP addresses in both instances. When coupled with Wraith Protocol Verge certainly becomes the only undetectable cryptocurrency.  Furthermore, transaction speed on Verge is light speed at 5 seconds only, using Simple Payment Verification technology. Verge also maintains a community feel since it’s not a private company. Community members are responsible for the direction of its technology and where the coin heads next. It currently offers a number of secure mobile wallets, including the Tor Android Wallet, which offers mobile anonymity, another big plus over Bitcoin.  Verges offers five different Proof-of-Work algorithms for mining. They include; Lyra2rev2, Scrypt, X17, blake2s and myr-groestl. Offering a choice of five different algorithms promotes inclusion, since a wider variety of users will now have an opportunity to not only mine but influence the network. Should one algorithm demand greater mining resources, users get an option of just switching to a different one.

Verge

Verge (XVG) is trending amid discussions about its potential, historical performance, and status as an ISO 20022 compliant cryptocurrency. The community is actively debating price predictions, potential breakout, and exchanges where XVG can be purchased, with some drawing comparisons to other privacy coins like $ZEC and $DASH.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its recent price surge and potential as a privacy-focused alternative to Bitcoin. Bullish sentiment is fueled by the coin's limited supply and increased adoption of shielded addresses, while some caution against a potential pullback after a significant run-up. The conversation also touches on Zcash's underlying technology and its potential for further growth.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

DAVE is trending due to positive analyst ratings and target price increases following strong Q3 earnings, with community members discussing the potential for continued growth and a bullish reversal. However, a Department of Justice lawsuit is also a key point of discussion, with some expressing concern over its potential impact on the company's future. Bullish investors see the dip as a buying opportunity and believe the company's fundamentals remain strong.

Alchemy Pay

Alchemy Pay is trending as the community discusses its potential for a significant run, possibly fueled by its focus on stablecoin transactions and cross-border payments. Recent partnerships, such as with Sony's Soneium and Ripple's RLUSD, are being highlighted alongside the anticipation for the launch of Alchemy Chain. Some traders express frustration with price movement, while others remain optimistic, citing the project's fundamentals and the nearing of max token supply.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap (UNI) is trending as the crypto community discusses its potential for growth and fee generation, alongside its role in shaping crypto regulation through the Ethereum Protocol Advocacy Alliance. Traders are evaluating entry points and anticipating a breakout, with some pointing to its undervalued status based on fees and TVL. The recent release of The Compact v1 is also being noted as a catalyst for the token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter picked up on Cel-Sci Corporation on Wednesday as investors awaited a key decision from the Saudi Food and Drug Authority (SFDA) on the company’s application for Breakthrough Medicine Designation for its cancer immunotherapy, Multikine.&nbsp;The ruling could come soon, as the SFDA’s 60-day review window is nearing its close.In August, Cel-Sci signed a Memorandum of Understanding with a leading Saudi pharmaceutical company, which submitted the application to the SFDA. A final commercialization agreement between the two partners is expected in the third quarter of 2025. The Saudi partner is also expected to facilitate reimbursement and accelerate Multikine’s sale and patient access in the Kingdom.The move has drawn growing interest from Saudi investment funds looking to back Multikine and Cel-Sci’s expansion across the Middle East and North Africa region.Multikine is designed to strengthen a patient’s immune system before surgery for newly diagnosed, untreated head and neck cancer. In a global Phase 3 study, the largest of its kind, the therapy improved five-year survival rates to 73% from 45% among patients receiving standard care alone, cutting the risk of death by half.If approved, Multikine would qualify for accelerated patient access and reimbursement under Saudi Arabia’s Breakthrough Medicine Program, which aims to fast-track treatments for serious or life-threatening diseases that meet unmet medical needs.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that Cel-Sci’s April update indicated the company was encouraged to seek conditional approval under the Breakthrough Therapy Designation. The filing was made around mid-August, suggesting a decision could be imminent.<stembedurl>https://stocktwits.com/NavyPatrol657/message/632324726</stembedurl>Another user expressed anticipation for an update from CEO Geert Kersten, while a third observed that the stock might remain subdued until the SFDA announcement.<stembedurl>https://stocktwits.com/prophet777/message/632356422</stembedurl><stembedurl>https://stocktwits.com/NoobFriendly/message/632216212</stembedurl><a href="https://stocktwits.com/symbol/CVM">CEL-SCI Corporation’s stock</a> has declined 18% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEL-SCI Corporation’s stock (CVM) has declined 18% so far in 2025.| Image source: Getty Images

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.

Equity

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical companies for a partnership that spans regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.<a href="https://stocktwits.com/symbol/CVM">CEL-SCI</a>’s shares were trading 33% higher at the time of writing.The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250711051288/en/CEL-SCI-to-Sign-Partnership-Agreement-With-Leading-Saudi-Arabian-Pharma-Company-for-Multikine-in-the-Treatment-of-Head-Neck-Cancer">said</a>. The partner will then file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA).Multikine is a cancer drug administered before surgery as a treatment for newly diagnosed and previously untreated head and neck cancer.If granted Breakthrough Medicine Designation, Multikine would immediately become available for patient access, reimbursement, or sale in Saudi Arabia. CEL-SCI said that it believes Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and is now developing a comprehensive commercialization plan with its Saudi pharma partner.In a study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% versus 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.The drug, given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.CEL-SCI also said on Friday that several Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.On Stocktwits, retail sentiment around CVM jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_11_59_25_AM_png_2f84b0779d.webp" alt="CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>CVM stock is down by 58% this year and by over 86% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-reportedly-stands-firm-on-eu-ad-model/ch8cirOR5Zw">Meta Reportedly Stands Firm On EU Ad Model Amid Looming Regulatory Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

Shares of Cel-Sci Corp ($CVM) slipped in the after-hours trading session on Friday following the company’s announcement of a share offering, with retail sentiment staying neutral. The purchase price of the offering, for its common stock par value of $0.01 per share, wasn’t immediately known. The last reported sale price of its stock was $0.70 per share. According to the company’s filing with the SEC, it is offering potential purchasers, along with related parties who own more than 4.99% of its outstanding common stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants exercisable at an exercise price of $0.01 per share.The purchase price of each pre-funded warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01, the statement said.The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full, the statement added. For each warrant, the number of shares of common stock on offer will be decreased on a one-for-one basis.&nbsp; Retail sentiment on Stocktwits has been ‘neutral’ compared to a week ago. Message volumes have been in the normal range. &nbsp;<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_11_21_09_AM_2d60d70bed.png" alt="Screenshot 2024-12-30 at 11.21.09 AM.png" width="1256" height="302"><figcaption>CVM sentiment meter and message volumes on Dec 29</figcaption></figure><stembedurl>https://stocktwits.com/phoenix31415/message/598120019</stembedurl>A ‘bearish’ commenter was not convinced on the terms.<stembedurl>https://stocktwits.com/ThaDreadPirate/message/598079934</stembedurl>The company has engaged ThinkEquity as the placement agent in connection with this offering.Cel-Sci develops immunotherapy products for the treatment of cancer and infectious diseases.Cel-Sci stock is down 77% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$7.09
Prev Close	$6.64
Open	$6.68
Dividend Yield	0.00%
50-Day Moving Average	$9.27
Beta	1.03
Avg. Volume	100,379.13
PE Ratio	-0.72

52-Week High	$32.70
52-Week Low	$1.98
Market Capitalization	$56.27M
EPS (Annual)	-$14.94
Price to Book	5.33
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CVM
Cel-Sci Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CVM News

CVMCel-Sci Corp.